This study, together with {1}, found that newer antimicrobial agents such as linezolid and tigecycline are tantalizingly active in vitro against the mycobacterium Mycobacterium abscessus but are rather disappointing, at least so far, for treating M. abscessus subspecies abscessus lung disease in vivo (see also {2}). This Recommendation is of an article referenced in an F1000Prime Report also written by David Griffith.